3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Leukemia, Lymphocytic, Chronic, B-Cell
4
Neoplasms
3
Leukemia
3
Breast Neoplasms
3
Preleukemia
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Precancerous Conditions
2
Neoplasms by Histologic Type
2
Myelodysplastic Syndromes
2
Multiple Chronic Conditions
2
Lymphoproliferative Disorders
2
Lymphoma
2
Lymphatic Diseases
2
Leukemia, Myeloid, Acute
2
Leukemia, Myeloid
2
Leukemia, Lymphoid
2
Leukemia, Biphenotypic, Acute
2
Leukemia, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Esophageal Neoplasms
2
Bone Marrow Diseases
2
Rectal Neoplasms
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Nasopharyngeal Neoplasms
1
Nasopharyngeal Carcinoma
1
Myeloproliferative Disorders
1
Interventions
perflutren
1
evening primrose oil
1
Tamoxifen
1
Sulfur Hexafluoride
1
Patient Reported Outcome Measures
1
Catheters
1
Blood Coagulation
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Cystic Fibrosis
×
Patient Reported Outcome Measures
×
Clear all
NCT03948958
2022-08-12
PREMO
Universitaire Ziekenhuizen KU Leuven
Phase NA
Completed
100 enrolled